Partial
Partially Aligned
Patient Risk:
Moderate
Summary
The claim that Ospomyv has a warning about severe hypocalcemia is directionally supported by the presence of a section 5.1 warning heading for 'Severe Hypocalcemia and Mineral Metabolism Changes,' but the specific phrasing limiting it to 'patients with advanced kidney disease' is not confirmed because the actual warning text for section 5.1 was not provided.
Category Scores
Accurate Statements
Denosumab labeling includes a warning topic related to severe hypocalcemia (via the existence of Warnings and Precautions section 5.1: 'Severe Hypocalcemia and Mineral Metabolism Changes').
Provided label excerpt indicates section 5.1 exists with heading 'Severe Hypocalcemia and Mineral Metabolism Changes' (warnings section 5.1 heading only; full text not provided).
Ospomyv is contraindicated in patients with pre-existing hypocalcemia, indicating that hypocalcemia is an important safety issue in the labeling.
Contraindications (4): 'Patients with hypocalcemia: Pre-existing hypocalcemia must be corrected prior to initiating therapy with Ospomyv [see Warnings and Precautions (5.1)].'
Unsupported Statements
WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE
The supplied label excerpts do not include the actual text of Warning/Precaution section 5.1, so the label-provided patient population specifically described as 'advanced kidney disease' cannot be verified.
Contradictions
Important Omissions
The actual Warning and Precautions (5.1) text that would confirm whether the warning is specifically limited to (or explicitly mentions) 'advanced kidney disease.'
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Using an unverified population qualifier ('advanced kidney disease') could misrepresent the labeling scope of the severe hypocalcemia warning, which affects how the warning may be interpreted. The general concern about hypocalcemia is supported, but the population specificity is not confirmed from the provided excerpt.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
The claim adds/assumes the specific patient population 'advanced kidney disease' for the severe hypocalcemia warning, but the supplied label excerpt does not provide the section 5.1 text needed to verify that linkage.
Suggested Improvement
Remove or qualify the 'advanced kidney disease' population language and reference only what is supported by the provided label excerpt (that there is a warning section 5.1 titled 'Severe Hypocalcemia and Mineral Metabolism Changes,' without asserting the specific population).